Fecal calprotectin in pediatric inflammatory bowel disease: A systematic review

Digestive Diseases and Sciences

Volumn 58, Issue 2, 2013, Pages 309-319

  Kostakis, Ioannis D ^a   Cholidou, Kyriaki G ^a   Vaiopoulos, Aristeidis G ^a   Vlachos, Ioannis S ^a   Perrea, Despina ^a   Vaos, George ^b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

Calprotectin; Crohn's disease; Inflammatory bowel disease; Pediatric; Ulcerative colitis

Indexed keywords

CALGRANULIN; CALGRANULIN A; CALGRANULIN B; BIOLOGICAL MARKER;

ARTICLE; CHILDHOOD DISEASE; CROHN DISEASE; ENTERITIS; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FECES LEVEL; FECES PROTEIN LEVEL; HUMAN; PRIORITY JOURNAL; RELAPSE; REMISSION; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; ULCERATIVE COLITIS; CHEMISTRY; CHILD; DIGESTIVE SYSTEM EXAMINATION; FECES; IMMUNOLOGY; METABOLISM; REVIEW;

BIOLOGICAL MARKERS; CHILD; DIAGNOSTIC TECHNIQUES, DIGESTIVE SYSTEM; FECES; HUMANS; INFLAMMATORY BOWEL DISEASES; LEUKOCYTE L1 ANTIGEN COMPLEX; SENSITIVITY AND SPECIFICITY;

MLCS; MLOWN;

EID: 84876326132     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-012-2347-5     Document Type: Article

References (61)

1. Benchimol EI, Fortinsky KJ, Gozdyra P, Van den Heuvel M, Van Limbergen J, Griffiths AM. Epidemiology of pediatric inflammatory bowel disease: a systematic review of international trends. Inflamm Bowel Dis. 2011;17:423-439.
2. Dubinsky M. Special issues in pediatric inflammatory bowel disease. World J Gastroenterol. 2008;14:413-420.
3. Carvalho R, Hyams JS. Diagnosis and management of inflammatory bowel disease in children. Semin Pediatr Surg. 2007;16:164-171.
4. Rufo PA, Bousvaros A. Challenges and progress in pediatric inflammatory bowel disease. Curr Opin Gastroenterol. 2007;23:406-412.
5. Kim SC, Ferry GD. Inflammatory bowel diseases in pediatric and adolescent patients: clinical, therapeutic, and psychosocial considerations. Gastroenterology. 2004;126:1550-1560.
6. Kim S, Ferry G. Inflammatory bowel diseases in children. Curr Probl Pediatr Adolesc Health Care. 2002;32:108-132.
7. Shikhare G, Kugathasan S. Inflammatory bowel disease in children: current trends. J Gastroenterol. 2010;45:673-682.
8. Baumgart DC. The diagnosis and treatment of Crohn's disease and ulcerative colitis. Dtsch Arztebl Int. 2009;106:123-133.
9. Romano C, Famiani A, Gallizzi R, Comito D, Ferrau' V, Rossi P. Indeterminate colitis: a distinctive clinical pattern of inflammatory bowel disease in children. Pediatrics. 2008;122:e1278-e1281.
10. Hugot JP, Bellaiche M. Inflammatory bowel diseases: the paediatric gastroenterologist's perspective. Pediatr Radiol. 2007;37:1065-1070.
11. Merchant A. Inflammatory bowel disease in children: an overview for pediatric healthcare providers. Gastroenterol Nurs. 2007;30:278-282.
12. Bousvaros A, Antonioli DA, Colletti RB, et al. Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn's and Colitis Foundation of America. J Pediatr Gastroenterol Nutr. 2007;44:653-674.
13. Leighton JA, Legnani P, Seidman EG. Role of capsule endoscopy in inflammatory bowel disease: where we are and where we are going. Inflamm Bowel Dis. 2007;13:331-337.
14. Diefenbach KA, Breuer CK. Pediatric inflammatory bowel disease. World J Gastroenterol. 2006;12:3204-3212.
15. Odze R. Diagnostic problems and advances in inflammatory bowel disease. Mod Pathol. 2003;16:347-358.
16. Jenkins HR. Inflammatory bowel disease. Arch Dis Child. 2001;85:435-437.
17. Wong A, Bass D. Laboratory evaluation of inflammatory bowel disease. Curr Opin Pediatr. 2008;20:566-570.
18. Fagerberg UL, Lööf L, Myrdal U, Hansson LO, Finkel Y. Colorectal inflammation is well predicted by fecal calprotectin in children with gastrointestinal symptoms. J Pediatr Gastroenterol Nutr. 2005;40:450-455.
19. Bonnín Tomàs A, Vila Vidal M, Rosell Camps A. Fecal calprotectin as a biomarker to distinguish between organic and functional gastrointestinal disease. Rev Esp Enferm Dig. 2007;99:689-693.
20. Sidler MA, Leach ST, Day AS. Fecal S100A12 and fecal calprotectin as noninvasive markers for inflammatory bowel disease in children. Inflamm Bowel Dis. 2008;14:359-366.
21. Quail MA, Russell RK, Van Limbergen JE, et al. Fecal calprotectin complements routine laboratory investigations in diagnosing childhood inflammatory bowel disease. Inflamm Bowel Dis. 2009;15:756-759.
22. Perminow G, Beisner J, Koslowski M, et al. Defective paneth cell-mediated host defense in pediatric ileal Crohn's disease. Am J Gastroenterol. 2010;105:452-459.
23. Canani RB, de Horatio LT, Terrin G, et al. Combined use of noninvasive tests is useful in the initial diagnostic approach to a child with suspected inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2006;42:9-15.
24. Bruzzese E, Raia V, Gaudiello G, et al. Intestinal inflammation is a frequent feature of cystic fibrosis and is reduced by probiotic administration. Aliment Pharmacol Ther. 2004;20:813-819.
25. Kolho KL, Raivio T, Lindahl H, Savilahti E. Fecal calprotectin remains high during glucocorticoid therapy in children with inflammatory bowel disease. Scand J Gastroenterol. 2006;41:720-725.
26. Ashorn S, Honkanen T, Kolho KL, et al. Fecal calprotectin levels and serological responses to microbial antigens among children and adolescents with inflammatory bowel disease. Inflamm Bowel Dis. 2009;15:199-205.
27. Diamanti A, Panetta F, Basso MS, et al. Diagnostic work-up of inflammatory bowel disease in children: the role of calprotectin assay. Inflamm Bowel Dis. 2010;16:1926-1930.
28. Grogan JL, Casson DH, Terry A, Burdge GC, El-Matary W, Dalzell AM. Enteral feeding therapy for newly diagnosed pediatric Crohn's disease: a double-blind randomized controlled trial with two years follow-up. Inflamm Bowel Dis. 2012;18:246-253.
29. Canani RB, Rapacciuolo L, Romano MT, et al. Diagnostic value of faecal calprotectin in paediatric gastroenterology clinical practice. Dig Liver Dis. 2004;36:467-470.
30. Perminow G, Brackmann S, Lyckander LG, et al. A characterization in childhood inflammatory bowel disease, a new population-based inception cohort from South-Eastern Norway, 2005-07, showing increased incidence in Crohn's disease. Scand J Gastroenterol. 2009;44:446-456.
31. Carroccio A, Iacono G, Cottone M, et al. Diagnostic accuracy of fecal calprotectin assay in distinguishing organic causes of chronic diarrhea from irritable bowel syndrome: a prospective study in adults and children. Clin Chem. 2003;49:861-867.
32. Paduchova Z, Durackova Z. Fecal calprotectin as a promising marker of inflammatory diseases. Bratisl Lek Listy. 2009;110:598-602.
33. Sipponen T, Kolho KL. Faecal calprotectin in children with clinically quiescent inflammatory bowel disease. Scand J Gastroenterol. 2010;45:872-877.
34. Vitali R, Stronati L, Negroni A, et al. Fecal HMGB1 is a novel marker of intestinal mucosal inflammation in pediatric inflammatory bowel disease. Am J Gastroenterol. 2011;106:2029-2040.
35. Diamanti A, Colistro F, Basso MS, et al. Clinical role of calprotectin assay in determining histological relapses in children affected by inflammatory bowel diseases. Inflamm Bowel Dis. 2008;14:1229-1235.
36. Nissen AC, van Gils CE, Menheere PP, van den Neucker AM, van der Hoeven MA, Forget PP. Fecal calprotectin in healthy term and preterm infants. J Pediatr Gastroenterol Nutr. 2004;38:107-108.
37. Diamanti A, Knafelz D, Panetta F, et al. Plasma citrulline as surrogate marker of intestinal inflammation in pediatric and adolescent with Crohn's disease: preliminary report. Int J Colorectal Dis. 2011;26:1445-1451.
38. Tomomasa T, Tajiri H, Kagimoto S, et al. Leukocytapheresis in pediatric patients with ulcerative colitis. J Pediatr Gastroenterol Nutr. 2011;53:34-39.
39. Bremner A, Roked S, Robinson R, Phillips I, Beattie M. Faecal calprotectin in children with chronic gastrointestinal symptoms. Acta Paediatr. 2005;94:1855-1858.
40. Joishy M, Davies I, Ahmed M, et al. Fecal calprotectin and lactoferrin as noninvasive markers of pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2009;48:48-54.
41. Gerasimidis K, Nikolaou CK, Edwards CA, McGrogan P. Serial fecal calprotectin changes in children with Crohn's disease on treatment with exclusive enteral nutrition: associations with disease activity, treatment response, and prediction of a clinical relapse. J Clin Gastroenterol. 2011;45:234-239.
42. Fagerberg UL, Lööf L, Lindholm J, Hansson LO, Finkel Y. Fecal calprotectin: a quantitative marker of colonic inflammation in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2007;45:414-420.
43. Olafsdottir E, Aksnes L, Fluge G, Berstad A. Faecal calprotectin levels in infants with infantile colic, healthy infants, children with inflammatory bowel disease, children with recurrent abdominal pain and healthy children. Acta Paediatr. 2002;91:45-50.
44. Turner D, Leach ST, Mack D, et al. Faecal calprotectin, lactoferrin, M2-pyruvate kinase and S100A12 in severe ulcerative colitis: a prospective multicentre comparison of predicting outcomes and monitoring response. Gut. 2010;59:1207-1212.
45. Bunn SK, Bisset WM, Main MJ, Gray ES, Olson S, Golden BE. Fecal calprotectin: validation as a noninvasive measure of bowel inflammation in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2001;33:14-22.
46. Bunn SK, Bisset WM, Main MJ, Golden BE. Fecal calprotectin as a measure of disease activity in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2001;32:171-177.
47. Turner D, Mack D, Leleiko N, et al. Severe pediatric ulcerative colitis: a prospective multicenter study of outcomes and predictors of response. Gastroenterology. 2010;138:2282-2291.
48. Canani RB, Terrin G, Rapacciuolo L, et al. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease. Dig Liver Dis. 2008;40:547-553.
49. Wiskin AE, Wootton SA, Cornelius VR, Afzal NA, Elia M, Beattie RM. No relation between disease activity measured by multiple methods and REE in childhood Crohn disease. J Pediatr Gastroenterol Nutr. 2012;54:271-276.
50. Walkiewicz D, Werlin SL, Fish D, Scanlon M, Hanaway P, Kugathasan S. Fecal calprotectin is useful in predicting disease relapse in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2008;14:669-673.
51. Aomatsu T, Yoden A, Matsumoto K, et al. Fecal calprotectin is a useful marker for disease activity in pediatric patients with inflammatory bowel disease. Dig Dis Sci. 2011;56:2372-2377.
52. Kostakis ID, Cholidou KG, Kallianidis K, Perrea D, Antsaklis A. The role of calprotectin in obstetrics and gynecology. Eur J Obstet Gynecol Reprod Biol. 2010;151:3-9.
53. McCormick MM, Rahimi F, Bobryshev YV, et al. S100A8 and S100A9 in human arterial wall. Implications for atherogenesis. J Biol Chem. 2005;280:41521- 41529.
54. Ehrchen JM, Sunderkötter C, Foell D, Vogl T, Roth J. The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer. J Leukoc Biol. 2009;86:557-566.
55. Stríz I, Trebichavský I. Calprotectin - a pleiotropic molecule in acute and chronic inflammation. Physiol Res. 2004;53:245-253.
56. Kannan S. Inflammation: a novel mechanism for the transport of extracellular nucleotide-induced arachidonic acid by S100A8/A9 for transcellular metabolism. Cell Biol Int. 2003;27:593-595.
57. Katashima T, Naruko T, Terasaki F, et al. Enhanced expression of the S100A8/A9 complex in acute myocardial infarction patients. Circ J. 2010;74:741-748.
58. Croce K, Gao H, Wang Y, et al. Myeloid-related protein-8/14 is critical for the biological response to vascular injury. Circulation. 2009;120:427-436.
59. Baumann M, Schmaderer C, Burkhardt K, et al. MRP8/14 is associated with systemic inflammation in stable coronary atherosclerosis in men. Eur J Clin Invest. 2011;41:1261-1267.
60. Ehlermann P, Eggers K, Bierhaus A, et al. Increased proinflammatory endothelial response to S100A8/A9 after preactivation through advanced glycation end products. Cardiovasc Diabetol. 2006;5:6.
61. van Rheenen PF, Van de Vijver E, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ. 2010;341:c3369.